Hot Investor Mandate: Korea-Based Pharma Interested in Partnering With Innovative Therapies in Immunology, Hematology, Rare Diseases

10 Dec

A Korea-based biopharmaceutical company that delivers life-saving and life-sustaining protein therapies and vaccines, has been dedicated to quality healthcare solutions more than half a century. The firm is open to global investment and licensing opportunities.

The firm’s R&D portfolio utilizes its expertise in plasma protein fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative therapeutics that address unmet medical needs and enhance current treatments in areas including Immunology, Hematology, rare disease, plasma protein therapies and vaccines. The firm is committed to broadening medical and scientific knowledge pertaining to its products, disease states of interest. The firm is actively looking for partners to help the firm grow the company’s businesses.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

<span>%d</span> bloggers like this: